From MarketBeat:

ImmunoGen, Inc. (NASDAQ:IMGN) saw a 5.6% increase in short interest in December, with 20,640,000 shares shorted. Ten analysts have rated the stock as “Hold” and three as “Buy,” with an average target price of $25.77. Senior vice presidents Theresa Wingrove and Renee Lentini have recently sold shares, while hedge funds have raised their stakes in the company.

ImmunoGen stock is up 0.2% to $29.76, with a market cap of $7.92 billion. The company announced $0.10 EPS last quarter, surpassing the $0.02 consensus estimate. ImmunoGen’s product candidates focus on developing and commercializing antibody-drug conjugates for cancer patients.

Wall Street has given ImmunoGen a “Hold” rating, with a consensus price target of $25.77. Insider buying and selling activities, as well as institutional inflows, are contributing to the stock’s momentum. Hedge funds and other institutional investors own 90.50% of the company’s stock.

Before you consider investing in ImmunoGen, you’ll want to check out MarketBeat’s list of seven stocks with long-term promising outlooks.



Read more: ImmunoGen, Inc. (NASDAQ:IMGN) Sees Significant Increase in Short Interest